Systematic Review and Meta-Analysis of Lipid Emulsion for Non-Local Anesthetic Poisoning.

J Med ToxicolAug 27, 2026 (epub)
Clinical ResearchEmergency MedicineOpen access

Zhengxin Tang, Megan Zhao, Alexandra Barabanova et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of intravenous lipid emulsion in treating non-local anesthetic poisonings across 12 studies involving 816 patients. The analysis found that lipid emulsion significantly reduced intensive care unit admissions (RR=0.70) and mortality (RR=0.65) compared to standard care, suggesting potential benefits in managing certain poisonings.

Key findings

  • Lipid emulsion reduced intensive care unit admission compared to standard care (RR=0.70; 95% CI: [0.53, 0.93]).
  • Mortality was significantly reduced with lipid emulsion (RR=0.65; 95% CI: [0.53, 0.80]).
  • Length of hospital admission decreased by an average of 34.16 hours with lipid emulsion.

Why it matters

The findings suggest that intravenous lipid emulsion may be a beneficial adjunct in the management of non-local anesthetic poisonings, potentially improving patient outcomes by reducing ICU admissions and mortality rates.

What to keep in mind

The evidence is limited by study heterogeneity and varying quality among the included studies.

Source

PubMed · PMID 42658387Free full text on PubMed Central

Published in J Med Toxicol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Emergency Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.